Advertisement Pharmaceutical Business review - Page 28 of 5266 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 25, 2026

MSD and Quotient collaborate on IBD drug targets

Merck & Co (MSD) has signed a multi-year research collaboration with Quotient Therapeutics to discover new drug targets for inflammatory bowel disease (IBD) using the latter’s somatic genomics platform technology.

The drug targets for IBD will be discovered using the somatic genomics platform technology. Credit: NMK-Studio / Shutterstock.com.